← Leaderboards
Barry D. Nelkin
Johns Hopkins University
$6,545,708
Attributed
$7,386,249
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$7,386,249 · 6
By mechanism
R01$5,507,174 · 3
P50$1,633,356 · 2
R21$245,719 · 1
Top collaborators
- Anirban Maitra5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- Richard J Jones$17,555,212
- Gregory D Kirk$60,349,977
- William George Nelson$34,555,726
- Elizabeth Marion Jaffee$29,780,612
Others in their field
Top investigators on “Therapeutic Target”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$399,079,477
- Judith S. Currier · University Of California Los Angeles$274,271,371
- Peter C Adamson · National Childhood Cancer Foundation$268,343,924
- Barbara Driver · Westat, Inc.$175,154,472
Research focus
Therapeutic TargetPathway InteractionsBaseCancer CellCell LineInhibitor/AntagonistGrowthIn VivoMediatingCombined Modality TherapyGenesGeneticMeksClinically RelevantCancer TypeAblationCellsCdk5 GeneAnimal ModelCancer Cell LineEngineeringEpithelial CellsCancer BiologyKnock-Out
Grant awards (24)
The Role of CDK5 in Metastasis$339,993
R01 · FY2012 · CA · contact PI
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development$330,091
R01 · FY2012 · CA · contact PI
The Role of CDK5 in Metastasis$339,993
R01 · FY2011 · CA · contact PI
EXPLOITATION OF RET INHIBITORS FOR TREATMENT OF THYROID CANCER$334,791
P50 · FY2011 · DE · contact PI
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development$330,091
R01 · FY2011 · CA · contact PI
The Role of CDK5 in Metastasis$350,509
R01 · FY2010 · CA · contact PI
EXPLOITATION OF RET INHIBITORS FOR TREATMENT OF THYROID CANCER$344,557
P50 · FY2010 · DE · contact PI
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development$340,300
R01 · FY2010 · CA · contact PI
The Role of CDK5 in Metastasis$350,509
R01 · FY2009 · CA · contact PI
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development$340,300
R01 · FY2009 · CA · contact PI
EXPLOITATION OF RET INHIBITORS FOR TREATMENT OF THYROID CANCER$333,911
P50 · FY2009 · DE · contact PI
The Role of CDK5 in Metastasis$350,509
R01 · FY2008 · CA · contact PI
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development$340,300
R01 · FY2008 · CA · contact PI
EXPLOITATION OF RET INHIBITORS FOR TREATMENT OF THYROID CANCER$324,744
P50 · FY2008 · DE · contact PI
EXPLOITATION OF RET INHIBITORS FOR TREATMENT OF THYROID CANCER$295,353
P50 · FY2007 · DE · contact PI
Ras/raf/rho in Lung Cancer Growth and Differentiation$339,263
R01 · FY2005 · CA
Ras/raf/rho in Lung Cancer Growth and Differentiation$339,263
R01 · FY2004 · CA
Ras/raf/rho in Lung Cancer Growth and Differentiation$339,263
R01 · FY2003 · CA
Ras/raf/rho in Lung Cancer Growth and Differentiation$339,263
R01 · FY2002 · CA
Exploitation of RET Inhibitors for Treatment of Thyroid Cancer$0
P50 · FY2002 · CA
Ras/raf/rho in Lung Cancer Growth and Differentiation$339,349
R01 · FY2001 · CA
NEUROTROPHIN RECEPTOR MEDIATED SUPPRESSION OF VEGF$122,719
R21 · FY2001 · CA
DIFFERENTIATION OF MEDULLARY THYROID CARCINOMA CELLS$398,178
R01 · FY2000 · CA
NEUROTROPHIN RECEPTOR MEDIATED SUPPRESSION OF VEGF$123,000
R21 · FY2000 · CA